Dr.ReproEndo said:

Dr.ObesityMed said: ...regarding the discontinuation data for cost and coverage...

Dr.ReproEndo said:

...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

1. Document medical necessity (BMI, comorbidities, failed alternatives)
2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
4. Request peer-to-peer review between your doctor and the plan's medical director
5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

pete_manc_UK said:

Financial impact of cost and coverage weight loss beyond medication cost: Groceries: SAVED $213/month (eating less) Restaurants: SAVED $203/month…

Saving this. It is the first explanation that did not require me to already understand it. Sending this to two other people who asked me the same thing last week.

Dr.ReproEndo said:

Dr.ObesityMed said: ...regarding the discontinuation data for cost and coverage...

My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.

stefan_berlin said:

Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…

Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives:

1. Prior authorization appeal with peer-to-peer review
2. Manufacturer copay card (for commercial insurance)
3. Patient assistance programs (Novo Nordisk, Eli Lilly)
4. Compounded medication from a 503B pharmacy ($119/month)
5. Canadian pharmacy (requires prescription, ~40-60% savings)

Don't let cost prevent access to effective treatment. There are options at every price point.

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Carry on.